BioLineRx Ltd. (BLRX) Scheduled to Post Quarterly Earnings on Tuesday
BioLineRx Ltd. (NASDAQ:BLRX) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, November 21st. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.
Shares of BioLineRx Ltd. (NASDAQ BLRX) opened at $1.01 on Tuesday. BioLineRx Ltd. has a one year low of $0.80 and a one year high of $1.38.
COPYRIGHT VIOLATION WARNING: “BioLineRx Ltd. (BLRX) Scheduled to Post Quarterly Earnings on Tuesday” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/14/biolinerx-ltd-blrx-scheduled-to-post-quarterly-earnings-on-tuesday.html.
BLRX has been the topic of a number of analyst reports. ValuEngine upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Roth Capital initiated coverage on shares of BioLineRx in a research note on Thursday, August 3rd. They set a “buy” rating and a $3.00 price objective on the stock. Zacks Investment Research upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. Maxim Group set a $3.00 price objective on shares of BioLineRx and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Finally, Oppenheimer Holdings, Inc. started coverage on shares of BioLineRx in a research note on Friday, August 4th. They set an “outperform” rating and a $3.00 price objective on the stock. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $2.88.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.